Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis

Masayoshi Harigai, Masayoshi Harigai

Abstract

To facitinib and baricitinib are two of the currently available Janus kinase (JAK) inhibitors for the treatment of patients with RA. Randomized controlled trials have shown that these JAK inhibitors are as efficacious as biological DMARDs. Safety profiles of these JAK inhibitors in randomized controlled trials and their long-term extension studies have been demonstrated; however, real world evidence remains to be established to bridge the gap between randomized controlled trials and rheumatology clinics. Fundamentally, no difference in the screening, prevention, and monitoring of infections between JAK inhibitors and biological DMARDs exists. However, increased risk of herpes zoster is probably common to all JAK inhibitors. No indication of increased risk for malignancy in patients with RA treated with JAK inhibitors has been reported. To evaluate risks of relatively rare serious adverse events such as thromboembolic events, gastrointestinal perforation, and interstitial lung disease in clinical settings, accumulation of cases with these events are needed. Continuous pharmacovigilance activity is absolutely warranted to establish the safety of JAK inhibitors in patients with RA and other rheumatic diseases.

Keywords: Janus kinase; RA; adverse event; baricitinib; herpes zoster; infection; malignancy; safety; thromboembolism; tofacitinib.

© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology.

Figures

Fig . 1
Fig. 1
Incidence rates of serious adverse events in patients with RA Incidence rates per 100 patient-years and 95% CIs of infection requiring hospitalization (for registries) or serious infection (for tofacitinib and baricitinib) (A) [11–13], all HZ, (B) [11, 12, 14], overall malignancy excluding non-melanoma skin cancer (C) [15–17], and lymphoma (D) [157–17] were plotted. Event rates in five large registries of RA (CORRONA, Institute of Rheumatology Rheumatoid Arthritis, Norfolk Arthritis Register, Swedish Rheumatology Quality of Care Register, and CORRONA International) were standardized for age and sex distribution in the RA clinical trial programme [11, 12]. For tofacitinib and baricitinib, crude incidence is presented. CORRONA: Consortium of Rheumatology Researchers of North America.

References

    1. Smolen JS, Landewé R, Bijlsma J. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960–77.
    1. Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol 2017;13:234–43.
    1. Wollenhaupt J, Silverfield J, Lee EB. et al. Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol 2014;41:837–52.
    1. Wollenhaupt J, Silverfield J, Lee EB. et al. Tofacitinib, an oral Janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension studies over 9 years (Abstract 1647). Arthritis Rheumatol 2017;69:Abstract 1647.
    1. Kremer J, Huizinga TWJ, Chen L. et al. Analysis of neutrophils, lymphocytes, and platelets in pooled phase 2 and phase 3 studies of baricitinib for rheumatoid arthritis (FRI0090). Ann Rheum Dis 2017;76:512.
    1. Kay J, Harigai M, Rancourt J. et al. Effects of baricitinib on haemoglobin and related laboratory parameters in rheumatoid arthritis patients (FRI0092). Ann Rheum Dis 2017;76:513.
    1. Tanaka Y, Yamaoka K, Ishida M. et al. Characterization of changes in lymphocyte (LYM) subsets in baricitinib (Bari)-treated patients (pts) with rheumatoid arthritis (RA) in a phase 3 study (RA-BEAM). Mod Rheumatol 2017;27:S357.
    1. Isaacs JD, Zuckerman A, Krishnaswami S. et al. Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials. Arthritis Res Ther 2014;16:R158.
    1. Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE.. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287–93.
    1. Crowson CS, Hoganson DD, Fitz-Gibbon PD, Matteson EL.. Development and validation of a risk score for serious infection in patients with rheumatoid arthritis. Arthritis Rheum 2012;64:2847–55.
    1. Yamanaka H, Askling J, Berglind N. et al. Infection rates in patients from five rheumatoid arthritis (RA) registries: contextualising an RA clinical trial programme. RMD Open 2017;3:e000498.
    1. Cohen SB, Tanaka Y, Mariette X. et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis 2017;76:1253–62.
    1. Winthrop K, Genovese M, Harigai M. et al. Serious infection and associated risk factors in patients with moderate to severe rheumatoid arthritis treated with baricitinib (OP0248). Ann Rheum Dis 2017;76:158.
    1. Atsumi T, Takeuchi T, Ishii T. et al. Herpes zoster in patients including Japanese with moderate to severe active rheumatoid arthritis treated with baricitinib, an oral JAK 1/JAK 2 inhibitor (Abstract W13-6). Mod Rheumatol 2017;27:S98.
    1. Genovese MC, Smolen JS, Takeuchi T. et al. Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 5.5 years: an updated integrated safety analysis (Abstract #511). Arthritis Rheumatol 2017;69:Abstract 511.
    1. Askling J, Berglind N, Franzen S. et al. How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registries. Ann Rheum Dis 2016;75:1789–96.
    1. Curtis JR, Lee EB, Kaplan IV. et al. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme. Ann Rheum Dis 2016;75:831–41.
    1. Ramiro S, Sepriano A, Chatzidionysiou K. et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2017;76:1101–36.
    1. Fleischmann R, Wollenhaupt J, Takiya L. et al. Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies. RMD Open 2017;3:e000491.
    1. Cohen S, Radominski SC, Gomez-Reino JJ. et al. Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol 2014;66:2924–37.
    1. Mimori T, Harigai M, Atsumi T. et al. Post-marketing surveillance of tofacitinib in Japanese patients with rheumatoid arthritis: an interim report of safety data (Abstract 431). Arthritis Rheumatol 2017;69(Suppl 10):Abstract 431.
    1. Smitten AL, Choi HK, Hochberg MC. et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum 2007;57:1431–8.
    1. Winthrop KL, Curtis JR, Lindsey S. et al. Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy. Arthritis Rheumatol 2017;69:1960–8.
    1. Curtis JR, Xie F, Yun H, Bernatsky S, Winthrop KL.. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis 2016;75:1843–7.
    1. Yamada T, Nakajima A, Inoue E. et al. Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan. Ann Rheum Dis 2006;65:1661–3.
    1. Askling J, Fored CM, Brandt L. et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005;52:1986–92.
    1. Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2006;2:602–10.
    1. Chiu YM, Lang HC, Lin HY. et al. Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan. Int J Rheum Dis 2014;17(Suppl 3):9–19.
    1. Ke WM, Chen LS, Parng IM, Chen WW, On AW.. Risk of tuberculosis in rheumatoid arthritis patients on tumour necrosis factor-alpha inhibitor treatment in Taiwan. Int J Tuberc Lung Dis 2013;17:1590–5.
    1. Baddley JW, Winthrop KL, Chen L. et al. Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study. Ann Rheum Dis 2014;73:1942–8.
    1. Winthrop KL, Park SH, Gul A. et al. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann Rheum Dis 2016;75:1133–8.
    1. Harigai M, Takeuchi T, Ishii T. et al. Long-term safety of baricitinib, an oral JAK1/JAK2 inhibitor, in patients with moderate to severe active rheumatoid arthritis: an integrated analysis (Abstract W13-1). Mod Rheumatol 2017;27:S97.
    1. Dixon WG, Watson K, Lunt M. et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368–76.
    1. Harigai M, Koike R, Miyasaka N.. Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med 2007;357:1874–6.
    1. Komano Y, Harigai M, Koike R. et al. Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum 2009;61:305–12.
    1. Winthrop KL, Novosad SA, Baddley JW. et al. Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance. Ann Rheum Dis 2015;74:2107–16.
    1. Winthrop KL, Lindsey S, Harigai M. et al. Potential opportunistic infections, and other infections of interest in patients with moderate to severe rheumatoid arthritis in the baricitinib program (Abstract 2787). Arthritis Rheumatol 2017;69:Abstract 2787.
    1. Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S.. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther 2015;17:212.
    1. Harigai M, Nanki T, Koike R. et al. Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: a nationwide cohort study in Japan. Mod Rheumatol 2016;26:642–50.
    1. Wu CY, Chen DY, Shen JL. et al. The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists: a nationwide cohort study. Arthritis Res Ther 2014;16:449.
    1. Mercer LK, Lunt M, Low AL. et al. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis 2015;74:1087–93.
    1. Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA. et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 2012;308:898–908.
    1. Schreiber RD, Old LJ, Smyth MJ.. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 2011;331:1565–70.
    1. Shimaoka H, Takeno S, Maki K. et al. A cytokine signal inhibitor for rheumatoid arthritis enhances cancer metastasis via depletion of NK cells in an experimental lung metastasis mouse model of colon cancer. Oncol Lett 2017;14:3019–27.
    1. Mariette X, Chen C, Biswas P, Kwok K, Boy MG.. Lymphoma in the tofacitinib rheumatoid arthritis clinical development program. Arthritis Care Res 2018;70:685–94.
    1. Maneiro JR, Souto A, Gomez-Reino JJ.. Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: systematic review, meta-analysis, and network meta-analysis. Semin Arthritis Rheum 2017;47:149–56.
    1. Mease PJ, Kremer J, Cohen S. et al. Thromboembolic events in the tofacitinib rheumatoid arthritis, psoriasis, psoriatic arthritis and ulcerative colitis development programs (Abstract 16L). Arthritis Rheumatol 2017;69:Abstract 16L.
    1. Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol 2015;12:464–74.
    1. Ungprasert P, Srivali N, Spanuchart I, Thongprayoon C, Knight EL.. Risk of venous thromboembolism in patients with rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol 2014;33:297–304.
    1. Schiff MH, Kremer JM, Jahreis A. et al. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 2011;13:R141.
    1. Koike T, Harigai M, Inokuma S. et al. Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. J Rheumatol 2014;41:15–23.
    1. Yamamoto K, Goto H, Hirao K. et al. Longterm safety of tocilizumab: results from 3 years of followup postmarketing surveillance of 5573 patients with rheumatoid arthritis in Japan. J Rheumatol 2015;42:1368–75.
    1. Xie F, Yun H, Bernatsky S, Curtis JR.. Risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments. Arthritis Rheumatol 2016;68:2612–7.
    1. Elli_Lilly_and_Company. Japanese Package Inserts of Baricitinib [in Japanese]. (16 July 2018, date last accessed).
    1. Pfizer. Japanese Package Inserts of Tofacitinib [in Japanese]. (16 July 2018, date last accessed).
    1. Sawada T, Inokuma S, Sato T. et al. Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology 2009;48:1069–72.
    1. Sato T, Inokuma S, Sagawa A. et al. Factors associated with fatal outcome of leflunomide-induced lung injury in Japanese patients with rheumatoid arthritis. Rheumatology 2009;48:1265–8.
    1. Furukawa H, Oka S, Shimada K, Tsuchiya N, Tohma S.. Rheumatoid_Arthritis_Interstitial_Lung_Disease_Study_Consortium. HLA-A*31: 01 and methotrexate-induced interstitial lung disease in Japanese rheumatoid arthritis patients: a multidrug hypersensitivity marker? Ann Rheum Dis 2013;72:153–5.
    1. Pfizer_Inc. Xeljanz, Highlights of Prescribing Information. 2018. (16 July 2018, date last accessed).
    1. Clowse ME, Feldman SR, Isaacs JD. et al. Pregnancy outcomes in the tofacitinib safety databases for rheumatoid arthritis and psoriasis. Drug Saf 2016;39:755–62.
    1. Elli_Lilly_and_company_Limited. Summary of Product Characteristics, Olumiant 2 mg and 4 mg Film-coated Tablets. 2018. (16 July 2018, date last accessed).
    1. Charles-Schoeman C, Wicker P, Gonzalez-Gay MA. et al. Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor. Semin Arthritis Rheum 2016;46:261–71.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe